BioInvent International AB (BINV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BioInvent International AB (BINV) has a cash flow conversion efficiency ratio of 0.082x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr66.78 Million ≈ $7.19 Million USD) by net assets (Skr810.74 Million ≈ $87.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BINV days of operational coverage to measure how many days the company can operate on defensive assets alone.
BioInvent International AB - Cash Flow Conversion Efficiency Trend (2002–2024)
This chart illustrates how BioInvent International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
BioInvent International AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioInvent International AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
NASDAQ:OACC
|
-0.001x |
|
HUYA Inc
F:HY5A
|
N/A |
|
Solara Active Pharma Sciences Limited
NSE:SOLARA
|
0.059x |
|
Sierra Madre Gold and Silver Ltd
V:SM
|
0.067x |
|
Alfen Beheer BV
AS:ALFEN
|
0.070x |
|
Circio Holding ASA
OL:CRNA
|
2.054x |
|
Sheng Yu Steel Co Ltd
TW:2029
|
-0.002x |
|
Yantai Changyu Pioneer Wine
SHE:200869
|
0.012x |
Annual Cash Flow Conversion Efficiency for BioInvent International AB (2002–2024)
The table below shows the annual cash flow conversion efficiency of BioInvent International AB from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see BINV market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr885.82 Million ≈ $95.33 Million |
Skr-380.47 Million ≈ $-40.94 Million |
-0.430x | -64.64% |
| 2023-12-31 | Skr1.31 Billion ≈ $140.95 Million |
Skr-341.69 Million ≈ $-36.77 Million |
-0.261x | -916.36% |
| 2022-12-31 | Skr1.61 Billion ≈ $172.84 Million |
Skr-41.23 Million ≈ $-4.44 Million |
-0.026x | +85.73% |
| 2021-12-31 | Skr1.37 Billion ≈ $147.11 Million |
Skr-245.84 Million ≈ $-26.46 Million |
-0.180x | -113.52% |
| 2020-12-31 | Skr743.50 Million ≈ $80.01 Million |
Skr-62.62 Million ≈ $-6.74 Million |
-0.084x | +88.62% |
| 2019-12-31 | Skr169.44 Million ≈ $18.23 Million |
Skr-125.43 Million ≈ $-13.50 Million |
-0.740x | +54.13% |
| 2018-12-31 | Skr87.62 Million ≈ $9.43 Million |
Skr-141.39 Million ≈ $-15.22 Million |
-1.614x | -176.96% |
| 2017-12-31 | Skr130.22 Million ≈ $14.01 Million |
Skr-75.88 Million ≈ $-8.17 Million |
-0.583x | -86.35% |
| 2016-12-31 | Skr230.44 Million ≈ $24.80 Million |
Skr-72.05 Million ≈ $-7.75 Million |
-0.313x | +87.31% |
| 2015-12-31 | Skr29.45 Million ≈ $3.17 Million |
Skr-72.57 Million ≈ $-7.81 Million |
-2.464x | -69.91% |
| 2014-12-31 | Skr52.43 Million ≈ $5.64 Million |
Skr-76.03 Million ≈ $-8.18 Million |
-1.450x | -30.04% |
| 2013-12-31 | Skr49.01 Million ≈ $5.27 Million |
Skr-54.65 Million ≈ $-5.88 Million |
-1.115x | +68.83% |
| 2012-12-31 | Skr47.62 Million ≈ $5.13 Million |
Skr-170.38 Million ≈ $-18.34 Million |
-3.578x | -790.00% |
| 2011-12-31 | Skr137.95 Million ≈ $14.85 Million |
Skr-55.45 Million ≈ $-5.97 Million |
-0.402x | +74.66% |
| 2010-12-31 | Skr74.19 Million ≈ $7.98 Million |
Skr-117.70 Million ≈ $-12.67 Million |
-1.586x | +30.58% |
| 2009-12-31 | Skr55.63 Million ≈ $5.99 Million |
Skr-127.14 Million ≈ $-13.68 Million |
-2.285x | -1308.90% |
| 2008-12-31 | Skr231.30 Million ≈ $24.89 Million |
Skr43.73 Million ≈ $4.71 Million |
0.189x | +220.57% |
| 2007-12-31 | Skr214.12 Million ≈ $23.04 Million |
Skr12.63 Million ≈ $1.36 Million |
0.059x | +106.42% |
| 2006-12-31 | Skr110.15 Million ≈ $11.85 Million |
Skr-101.23 Million ≈ $-10.89 Million |
-0.919x | -90.80% |
| 2005-12-31 | Skr219.00 Million ≈ $23.57 Million |
Skr-105.48 Million ≈ $-11.35 Million |
-0.482x | -15.43% |
| 2004-12-31 | Skr212.68 Million ≈ $22.89 Million |
Skr-88.74 Million ≈ $-9.55 Million |
-0.417x | -92.09% |
| 2003-12-31 | Skr304.96 Million ≈ $32.82 Million |
Skr-66.25 Million ≈ $-7.13 Million |
-0.217x | -710.31% |
| 2002-12-31 | Skr394.25 Million ≈ $42.43 Million |
Skr-10.57 Million ≈ $-1.14 Million |
-0.027x | -- |
About BioInvent International AB
BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more